|
業務類別
|
Biotechnology |
|
業務概覽
|
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment. |
| 公司地址
| 900 Chesapeake Drive, Redwood City, CA, USA, 94063 |
| 電話號碼
| +1 650 665-9295 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.boltbio.com |
| 員工數量
| 23 |
| Mr. Grant A. Yonehiro |
Chief Operating Officer and Chief Business Officer |
美元 463.50K |
28/04/2026 |
| Ms. Sarah Nemec |
Senior Vice President, Finance and Principal Accounting Officer |
-- |
28/04/2026 |
| Mr. William P. Quinn |
Director, Chief Financial Officer, President and Chief Executive Officer |
美元 463.50K |
28/04/2026 |
|
|
| Dr. Jakob Dupont, M.D.,PhD |
Independent Director |
28/04/2026 |
| Ms. Kathleen D. Laporte |
Independent Director |
28/04/2026 |
| Dr. Nicole Onetto, M.D. |
Independent Director |
28/04/2026 |
| Mr. Brian O'Callaghan |
Chairman of the Board |
28/04/2026 |
| Ms. Laura Berner |
Independent Director |
28/04/2026 |
| Mr. William P. Quinn |
Director, Chief Financial Officer, President and Chief Executive Officer |
28/04/2026 |
|
|
|
|
